MetaCap

Korro Bio (KRRO) vs Entrada Therapeutics (TRDA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Korro Bio (KRRO) has outperformed Entrada Therapeutics (TRDA) over the past year, gaining 93.9% versus a loss of 57.0%. Over five years, TRDA leads with a -85.0% price change compared with -95.7% for KRRO. Entrada Therapeutics is the larger company by market cap ($170.3 million vs $167.2 million), about 1.0 times the size, while Korro Bio is growing revenue faster (+181.5% vs -87.9%).

Entrada Therapeutics converts more of its revenue into profit, with a net margin of -565.5% versus -1834.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KRRO+93.95%TRDA-56.97%
+176%+54%-68%
Nov 21, 20251 yearNov 20, 2026
KRRO-95.95%TRDA-86.73%
+5%-49%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KRRO versus TRDA key metrics
MetricKRROTRDA
Share price$12.18$4.35
Market cap$167.18M$170.30M
1-day change-0.08%-6.25%
YTD return+52.06%-57.68%
1-year return+93.95%-56.97%
5-year return-95.67%-84.95%
EPS (TTM)$-8.89$-3.84
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$6.39M$25.42M
Revenue growth (YoY)+181.46%-87.94%
Net income (latest FY)$-117.26M$-143.75M
Operating margin-1906.37%-621.13%
Net margin-1834.48%-565.48%
52-week high$17.35$16.45
52-week low$5.20$4.11
Distance from 52-week high-29.81%-73.56%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+76.52%+308.05%
Average volume186.03K401.15K
Shares outstanding13.73M39.15M
Employees58152
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KRRO has outperformed TRDA by 150.9 percentage points over the past year.
  • Entrada Therapeutics is more profitable, keeping -565.5 cents of every revenue dollar as net income versus -1834.5 cents for Korro Bio.
  • Korro Bio grew revenue faster in its latest fiscal year (+181.46% vs -87.94%).

About Korro Bio

KRRO stock →

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees

About Entrada Therapeutics

TRDA stock →

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 152 employees

KRRO vs TRDA FAQ

Which is bigger, Korro Bio or Entrada Therapeutics?

Entrada Therapeutics (TRDA) is larger, with a market capitalization of $170.30M compared with $167.18M for Korro Bio (KRRO).

Which stock has performed better over the past year, KRRO or TRDA?

KRRO returned +93.95% over the past 12 months, compared with -56.97% for TRDA (price return, excluding dividends). Past performance does not predict future results.

Are Korro Bio and Entrada Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons